Gemzar (Gemcitabine) and Alimta (Pemetrexed) in the Treatment of Patients With Recurrent Platinum-Sensitive and Platinum-Resistant Ovarian or Peritoneal Cancer

Inclusion Criteria: * Patients must have disease that can be measured. * Patients must meet criteria for either platinum-resistant or platinum-sensitive ovarian or peritoneal cancer. * Patients may only have had one prior platinum-based chemotherapy regimen. * Patients must be willing and able to stop all aspirin and NSAID medications immediately before and for a time after each treatment cycle (approx. 5-8 days) * Patients must have normal kidney function. Exclusion Criteria: * Patients may not have a Low Malignant Potential or Borderline Ovarian Tumor. * Patients may not have received pelvic or abdominal radiotherapy. * Patients must not have evidence of or received treatment for another cancer within the last 5 years. * Patients must not have been diagnosed with a heart attack in the last 6 months. * Patients who are unwilling or unable to take folic acid tablets, vitamin B12 injections or dexamethasone tablets.